

RICT 2013

Drug Discovery and Selection

Confirmed Speakers

Confirmed Speakers To Date

Natural Products as Leads for Drug Discovery



Prof. Karl-Heinz ALTMANN
(ETH ZURICH, Zurich, Switzerland)

Strategies and Challenges for the Next Generation of Therapeutic Antibodies and Derivatives



Dr Alain BECK
(PIERRE FABRE, St Julien-en-Genevois, France)

Beyond Antithrombotics: Synthetic Approaches to Unravel New Therapeutic Potentials for Glycosaminoglycans



Prof. David BONNAFFÉ
(UNIVERSITY PARIS-SUD, Orsay, France)

Systemic Safety by Design: a Novel Retinoic Acid Receptor Agonist for Dermatological Indications with Specific Design Parameters for Topical Administration to Manage Safety



Dr Claire BOUIX-PETER
(GALDERMA R&D, Sophia-Antipolis, France)

The Discovery of Small Molecule Inhibitors of Jumonji Enzymes: Probing the Epigenome



Dr Jack BROWN
(EPINOVA DPU, II TAU, GLAXOSMITHKLINE, Stevenage, United Kingdom)

Antibody-Drug Conjugates: A Promising new Paradigm in Cancer Therapy



Dr Ravi CHARI
(IMMUNOGEN, Waltham, United States)

Structure and Fragment Based Drug Design for G Protein-Coupled Receptors



Dr Miles CONGREVE
(HEPTARES, Welwyn Garden City, United Kingdom)

Fragment Screening and Drug Design with Fluorine NMR Spectroscopy



Dr Claudio DALVIT
(UNIVERSITY OF NEUCHÂTEL, Neuchâtel, Switzerland)

Discovery of Highly Potent, Selective and Efficacious Cathepsin S Inhibitors

RICT 2013

Drug Discovery and Selection

Confirmed Speakers



Dr Wolfgang HAAP
(F. HOFFMANN-LA ROCHE, Basel, Switzerland)

Discovery and Optimization of Indoline Pyrimidone PI3Kb Inhibitors for the Treatment of PTEN-deficient Cancers



Dr Frank HALLEY
(SANOFI, Vitry-sur-Seine, France)

DAAO Inhibitors as Clinical Candidates



Dr Michele HEFFERNAN
(SUNOVION PHARMACEUTICALS, Marlborough, United States)

High Confidence Target and Pathway Prediction Using a Robust Chemogenomic Platform



Dr Stephen HELLIWELL
(NOVARTIS, Basel, Switzerland)

The European Lead Factory - A Novel Discovery Partnership Model



Dr Jörg HUESER
(BAYER PHARMA, Wupperthal, Germany)

Targeted Cancer Chemotherapy: Developing NextGen Antibody Drug Conjugates & Key factors that Influence ADC Therapeutics



Dr Jagath Reddy JUNUTULA
(GENENTECH, South San Francisco, United States)

ADMET Modelling: Where is it Worth the Effort?



Dr Richard LAW
(EVOTEC, Abingdon, United Kingdom)

Of Ionic Channels, Venom Toxins and Other Natural Substances ... and Diseases



Prof. Michel LAZDUNSKI
(INSTITUT DE PHARMACOLOGIE MOLECULAIRE ET CELLULAIRE (IPMC), Nice, France)

Improving Compound Quality in Medicinal Chemistry



Dr Paul LEESON
(ASTRAZENECA, United Kingdom)

SOM230: A New Therapeutic Modality for Cushing's Disease

RICT 2013

Drug Discovery and Selection

Confirmed Speakers



Dr Ian LEWIS
(NOVARTIS, Basel, Switzerland)

How Animal Venoms Help to Understand Pain: Acid-Sensing Ion Channels in the Pain Pathway



Dr Eric LINGUEGLIA
(CNRS-UNIVERSITY OF NICE SOPHIA ANTIPOLIS, Valbonne, France)

Developing New Tools for Cancer Diagnostics and Therapeutics: Fluorescent Peptide Biosensors of Cyclin-Dependent Kinases



Dr May MORRIS
(CENTRE DE RECHERCHE EN BIOCHIMIE MACROMOLÉCULAIRE (CRBM) - CNRS, Montpellier, France)

Validation of Protein Kinases as Drug Targets in the African Trypanosome



Prof. Jeremy MOTTRAM
(UNIVERSITY OF GLASGOW, Glasgow, United Kingdom)

All in Good Time, Exploiting Residence Time to Improve Fragment Based Drug Discovery



Dr James MURRAY
(VERNALIS, Cambridge, United Kingdom)

Ion Channel Drug Discovery: a Medicinal Chemistry Perspective



Dr Robert OWEN
(PFIZER NEUSENTIS, Cambridge, United Kingdom)

GLPG0974, a FFA2 Antagonist from Hit to Clinic



Dr Laurent SANIERE
(GALAPAGOS, Romainville, France)

Discovery of Potent and Selective Inhibitors of the Cardiac Sodium/Calcium Exchanger (NCX-1)



Dr Hartmut SCHIROK
(BAYER, Wuppertal, Germany)

Molecular Networks : Drug Action and Genome-Informed Medicine



Prof. Giulio SUPERTI-FURGA
(RESEARCH CENTER FOR MOLECULAR MEDICINE (CEMM), Vienna, Austria)

Drugs for Bad Bugs - Strategies to Address Infections by Multidrug-resistant Bacteria

RICT 2013

Drug Discovery and Selection

Confirmed Speakers



Dr Jean-Philippe SURIVET
(ACTELION, Allschwil, Switzerland)

Allosteric Modulation of the Chemokine Receptor CXCR3



Dr Nuska TSCHAMMER
(UNIVERSITY OF ERLANGEN-NÜRNBERG, Erlangen, Germany)

Drug Discovery for Diseases of the Developing World



Prof. Paul WYATT
(UNIVERSITY OF DUNDEE, Dundee, United Kingdom)